Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. MarÃa-Victoria Mateos
University of Salamanca, Spain
Prof. MarÃa-Victoria Mateos, MD, PhD, is the head of the Myeloma and Clinical Trials Unit in the Haematology Department and a professor of medicine at the University of Salamanca, Spain. read more
Prof. Mateos serves as coordinator of the Grupo Español de Mieloma Múltiple (GEM; Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials especially in the setting of transplant-ineligible and smoldering myeloma and these trials have profoundly influenced current options for the management of these patient populations.Â
Prof. Mateos has published over 400 papers in international journals with an H index of 96. She is also a member of the International Myeloma Working Group (IMWG), the International Myeloma Society (IMS), the European Hematology Association (EHA) and the American Society of Hematology (ASH).Â
Prof. Mateos served on the ASH Scientific Committee of Plasma Cell Neoplasia between 2015–2019 and the EHA Scientific Program Committee and Advisory Board from 2013–2020; in 2019 she was chair of the Scientific Program Committee. She served a 4-year mandate as a councillor on the EHA Board from 2015 for a four-year mandate and she is now a member of the IMS Executive Board, the European School of Haematology (ESH) Scientific Committee and the American Society of Clinical Oncology Scientific Program Committee. She received the Brian Durie Outstanding Achievement Award in 2019; the Bart Barlogie Clinical Investigator Award in 2022, recognizing excellence in myeloma research; and the Robert A Kyle Lifetime Achievement Award in 2023. In October 2022 she began a 4-year mandate as president of the Spanish Society of Hematology.
Prof. MarÃa-Victoria Mateos discloses: Advisory board or panel and speaker bureau fees from AbbVie, Amgen, Celgene, GSK, Janssen, Kite, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Stemline and Takeda.
Dr Rakesh Popat
University College London Hospitals, UK
Dr Rakesh Popat is an associate professor at University College London and a consultant haematologist at University College London Hospitals (UCLH) with an interest in multiple myeloma. read more
He graduated from Guy’s and St. Thomas’ Medical School in London and trained in haematology at St. Bartholomew’s and the Royal London Hospitals. During this time he completed a PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana-Farber Cancer Institute, Boston, USA.
He has particular experience with novel treatments including immunotherapies, such as CAR-T cell therapy and new antibody approaches. At University College Hospital, he leads the myeloma clinical trials programme and is the cancer lead at the National Institute for Health and Care Research (NIHR) UCLH Clinical Research Facility. Regionally, he is the NIHR North Thames clinical research network haemato-oncology lead.
Dr Popat is the chair of the UK Myeloma Research Alliance, the National Cancer Research Institute’s myeloma working group, is on the executive board of the UK Myeloma Forum, and the young board of the European Myeloma Network. He is the chief investigator for a number of relapsed myeloma studies and the principal investigator for the NIHR Health Informatics Collaborative Myeloma Theme.
Dr Rakesh Popat discloses: Advisory board or panel fees from GSK, Johnson & Johnson, Roche and Sanofi. Consultant fees from GSK and Regeneron. Grants/research support from GSK and Pfizer. Other financial or material support (royalties, patent, etc) from AbbVie, BMS, GSK, Johnson & Johnson and Pfizer. Speaker Bureau fees from Pfizer.
Prof. Evangelos Terpos
National and Kapodistrian University of Athens, Greece
Prof. Evangelos Terpos, MD, PhD, is a professor of haematology and director of the Stem Cell Transplantation Unit at the National and Kapodistrian University of Athens, School of Medicine in Athens, Greece. read more
His main research interest is the biology and management of bone disease in multiple myeloma. He also studies the role of modern imaging (MRI, PET/CT) and of minimal residual disease (MRD) in plasma cell neoplasms. In the clinical research era, Prof. Terpos is the principal investigator of several studies with novel agents (i.e. belantamab mafodotin, selinexor, T-cell engagers) in the field of myeloma.Â
His research has been reported in more than 750 papers in peer-reviewed journals. Prof. Terpos has more than 37,000 citations and an h-index of 92 in the Institute for Scientific Information/Web of Knowledge, and more than 58,000 citations and an h-index of 112 in Google Scholar.
Prof. Terpos is a councillor on the European Hematology Association (EHA) Board, he co-chairs the bone subcommittee of the International Myeloma Working Group and he is a member of the guideline subgroup of the European Myeloma Network. Prof. Terpos is also a member of the education and publication committees of the International Myeloma Society (IMS), and he is the vice president of the Greek Myeloma Study Group.
He has given lectures at American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) meetings, as well as several national meetings, and led IMS International Myeloma Workshops. He is associate editor for myeloma of the American Journal of Hematology and of Clinical Lymphoma, Myeloma & Leukemia and a member of the editorial board for Blood Cancer Journal.
Prof. Evangelos Terpos discloses: Employee or independent contractor fees from Amgen, Antengene, AstraZeneca, BMS, GSK, Janssen, Pfizer, Sanofi, Swixx Biopharma and Takeda. Advisory board or panel fees from BMS, GSK, Janssen, Pfizer and Swixx BioPharma. Grants/research support from GSK, Janssen, Sanofi and Takeda.
